Gabapentin Hub
FDA-approved uses for gabapentin products
Approval describes the uses that were studied and labeled for a specific product. It is not a personal treatment recommendation, and it is not the same for every gabapentin-related tablet.
What an approved indication is
An FDA-approved indication is a use for which the manufacturer submitted evidence and FDA agreed that the product’s labeling may describe that use. It is tied to a specific product, population, and often a specific role (for example, add-on seizure therapy rather than every form of epilepsy).
Approval does not mean the medicine is the only option, that it will help every person with that condition, or that other uses are automatically unsafe. It also does not mean a website can recommend the drug. Individual decisions remain with the prescriber and patient.
Immediate-release gabapentin (Neurontin and many generics)
Current Neurontin labeling lists two indications. The first is management of postherpetic neuralgia in adults. Postherpetic neuralgia is pain that continues after a shingles rash. Shingles is caused by reactivation of the varicella-zoster virus; CDC describes the typical painful blistering rash and notes that some people have lingering nerve pain afterward.
The second labeled use is adjunctive therapy for partial-onset seizures, with or without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy. “Partial-onset” (focal) seizures begin in a limited brain network. “Secondary generalization” means a focal seizure can spread and look like a whole-brain convulsion. Adjunctive therapy means gabapentin was studied added to other anti-seizure medicines.
Those labeled uses do not include every neuropathy, back pain, migraine, anxiety disorder, insomnia, or alcohol-withdrawal protocol that appears in internet discussions. Some of those topics are off-label and belong in a separate conversation with a clinician.
Gralise: postherpetic neuralgia only, once daily
Gralise labeling indicates the product for management of postherpetic neuralgia. It is not labeled for epilepsy. The prescribing information emphasizes that Gralise is not interchangeable with other gabapentin products because differing pharmacokinetic profiles affect how often it is given.
The labeled adult regimen is titrated to 1,800 mg once daily with the evening meal, with tablets swallowed whole. That schedule is a labeled example for that product, not a personal dose for someone taking a different gabapentin capsule. The safety and effectiveness of Gralise in epilepsy have not been studied, according to its labeling.
Horizant: restless legs syndrome and postherpetic neuralgia
Horizant (gabapentin enacarbil) is labeled for treatment of moderate-to-severe primary restless legs syndrome in adults and for management of postherpetic neuralgia in adults. Restless legs syndrome is a neurologic condition with an urge to move the legs, often worse at rest and in the evening. Horizant is not labeled as a general insomnia medicine.
Tablets are to be swallowed whole and taken with food. Labeling states Horizant is not substitutable with other gabapentin products. The Medication Guide warns patients not to take other gabapentin drugs while taking Horizant.
What approval does not settle
A labeled indication still leaves open questions of kidney dosing, other medicines, pregnancy, driving, and whether the expected benefit outweighs adverse effects for that person. Pediatric seizure dosing, when used, is weight-based and age-grouped in Neurontin labeling and must be calculated by the prescriber—not copied from an adult bottle.
If your prescription is for a condition that is not listed on the package insert you were given, that may be intentional off-label prescribing. Ask the clinician to explain the goal, the evidence they are relying on, and what would lead them to stop or change the plan. Do not assume an unlisted use is either “illegal” or “guaranteed.”
Key points
- Neurontin-type gabapentin is labeled for adult postherpetic neuralgia and as add-on therapy for partial-onset seizures in patients 3 years and older.
- Gralise is labeled only for postherpetic neuralgia and is not interchangeable with other gabapentin products.
- Horizant is labeled for adult restless legs syndrome and adult postherpetic neuralgia and is a different chemical product (a prodrug).
- A labeled use is not a personal prescription, and an unlabeled use is not automatically inappropriate—or automatically appropriate.
Questions readers often ask
Is gabapentin FDA-approved for diabetic nerve pain?
Immediate-release gabapentin’s labeled nerve-pain indication is postherpetic neuralgia, not diabetic peripheral neuropathy. Pregabalin has a labeled diabetic-neuropathy indication; that fact does not make the two drugs interchangeable. Any use of gabapentin for diabetic nerve pain would be off-label and would need a clinician’s judgment.
Is gabapentin FDA-approved for fibromyalgia?
No. Pregabalin has a fibromyalgia indication; gabapentin products described on this page do not carry that labeled use. Off-label prescribing, if it occurs, is a clinical decision—not a use this site recommends.
Sources
- DailyMed: NEURONTIN (gabapentin) capsules, tablets, and oral solution — U.S. National Library of Medicine
- DailyMed: GRALISE (gabapentin) tablets — U.S. National Library of Medicine
- DailyMed: HORIZANT (gabapentin enacarbil) extended-release tablets — U.S. National Library of Medicine
- CDC: Shingles (herpes zoster) signs and symptoms — Centers for Disease Control and Prevention
- FDA prescribing information: GRALISE (gabapentin) — U.S. Food and Drug Administration
- FDA prescribing information: HORIZANT (gabapentin enacarbil) — U.S. Food and Drug Administration
- MedlinePlus: Gabapentin — MedlinePlus / National Library of Medicine